Atrium Therapeutics, Inc. (RNA) Income Statement
RNA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRNA revenue and net income
Where RNA's revenue goes
2025Each bar shows an amount and its share of revenue. RNA kept −411.9% of revenue as net income.
RNA profit margins
RNA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +70.9% | +26.4% | +22.4% | +5.1% |
| Gross profit | +70.9% | +26.4% | +22.4% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RNA quarterly EPS vs estimates
Atrium Therapeutics beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 12, 2026 (estimate $-1.70).
RNA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.6M | $10.9M | $9.6M | $9.2M | $9.3M | $6.8M | $2.3M | $379,000 | $13.1M | $10.4M |
| Cost of revenue | $4.2M | $2.8M | $2.1M | $1.4M | $639,000 | $37.6M | $14.5M | $8.4M | $32.5M | $22.7M |
| Gross profit | $18.6M | $10.9M | $7.5M | $9.2M | $9.3M | $6.8M | $2.3M | −$8.1M | −$19.4M | −$12.4M |
| Research & development | $53.8M | $303.6M | $191.0M | $150.4M | $101.2M | $37.6M | $14.5M | $8.4M | $25.4M | $19.0M |
| Sales, general & admin | $41.7M | $86.2M | $56.3M | $37.7M | $26.2M | $13.5M | $5.1M | $2.4M | — | — |
| Total operating expenses | $95.4M | $389.8M | $243.1M | $188.1M | $127.4M | $51.1M | $19.7M | $10.9M | — | — |
| Operating income | −$76.8M | −$378.9M | −$235.6M | −$178.9M | −$118.1M | −$44.3M | −$17.3M | −$10.5M | — | — |
| Interest income | — | $56.9M | $20.3M | $5.0M | $104,000 | $206,000 | $161,000 | $0 | — | — |
| Interest expense | — | — | — | $5.7M | $639,000 | $209,000 | $7.4M | $718,000 | $0 | $0 |
| Income before taxes | −$76.8M | −$322.3M | −$212.2M | −$174.0M | −$118.0M | −$44.4M | −$24.7M | −$11.2M | — | — |
| Income taxes | −$142,000 | — | $1.9M | −$4.9M | −$639,000 | −$373,000 | $7.4M | $718,000 | — | — |
| Net income | −$76.7M | −$322.3M | −$212.2M | −$169.1M | −$117.4M | −$44.0M | −$24.7M | −$11.9M | — | — |
| EBITDA | −$76.5M | −$376.2M | −$233.5M | −$177.5M | −$117.4M | −$43.9M | −$17.0M | −$10.1M | — | — |
| EPS (diluted) | −$4.97 | −$2.89 | −$2.90 | −$3.33 | −$2.84 | −$2.85 | −$1.20 | — | −$0.11 | — |
| Gross margin | 100.0% | 100.0% | 78.0% | 100.0% | 100.0% | 100.0% | 100.0% | −2,125.9% | −148.4% | −119.7% |
| Operating margin | −412.6% | −3,477.4% | −2,464.4% | −1,939.6% | −1,265.8% | −652.4% | −747.4% | −2,769.9% | — | — |
| Net margin | −411.9% | −2,957.7% | −2,219.9% | −1,833.0% | −1,258.5% | −648.0% | −1,066.6% | −3,148.8% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $19.6M | $859,000 | $12.5M | $3.8M | $1.6M | $3.0M | $2.3M | $2.0M | $3.5M | $2.2M | $2.8M |
| Cost of revenue | $343,000 | $151,000 | $1.5M | $0 | $138.1M | $0 | $738,000 | $710,000 | $687,000 | $641,000 | $615,000 | $47.7M |
| Gross profit | $2.7M | $19.5M | $859,000 | $12.5M | −$134.3M | $1.6M | $3.0M | $2.3M | $1.4M | $2.9M | $1.6M | −$44.9M |
| Research & development | $15.3M | $16.7M | $18.5M | $154.9M | $138.1M | $99.5M | $95.6M | $77.2M | $63.9M | $66.8M | $52.8M | $47.7M |
| Sales, general & admin | $10.3M | $20.3M | $30.4M | $5.8M | $36.9M | $33.6M | $28.3M | $23.3M | $21.4M | $14.5M | $16.7M | $13.7M |
| Total operating expenses | $25.3M | $36.8M | $48.9M | $8.5M | $36.9M | $133.1M | $124.0M | $100.5M | $84.0M | $80.1M | $68.3M | $13.7M |
| Operating income | −$22.6M | −$17.3M | −$48.0M | −$8.5M | −$171.1M | −$131.5M | −$121.0M | −$98.1M | −$82.6M | −$77.2M | −$66.7M | −$58.6M |
| Interest income | $2.1M | — | — | $14.7M | $14.5M | $16.2M | $18.5M | $18.0M | $11.9M | $8.4M | $6.4M | $6.3M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $391,000 | — |
| Income before taxes | −$20.2M | −$16.6M | −$48.0M | −$8.5M | −$157.3M | −$115.8M | −$102.3M | −$80.4M | −$70.8M | −$68.9M | −$60.4M | −$52.4M |
| Income taxes | — | — | $34,000 | −$176,000 | — | — | — | — | — | $597,724 | −$1 | −$6.3M |
| Net income | −$20.2M | −$16.6M | −$48.1M | −$8.3M | −$157.3M | −$115.8M | −$102.3M | −$80.4M | −$70.8M | −$68.9M | −$60.4M | −$52.4M |
| EBITDA | −$22.3M | −$16.5M | −$47.9M | −$8.4M | −$170.3M | −$130.7M | −$120.3M | −$97.4M | −$81.9M | −$76.5M | −$66.1M | −$58.1M |
| EPS (diluted) | −$1.18 | −$0.97 | −$1.59 | −$1.27 | −$1.21 | −$0.90 | −$0.80 | −$0.65 | −$0.65 | −$0.79 | −$0.79 | −$0.71 |
| Gross margin | 88.6% | 99.2% | 100.0% | 100.0% | −3,490.5% | 100.0% | 100.0% | 100.0% | 66.4% | 81.9% | 72.0% | −1,593.2% |
| Operating margin | −752.9% | −88.0% | −5,592.0% | −67.8% | −4,448.7% | −8,360.9% | −4,069.6% | −4,200.9% | −4,040.4% | −2,178.6% | −3,043.5% | −2,080.4% |
| Net margin | −672.0% | −84.7% | −5,595.9% | −66.4% | −4,089.3% | −7,360.0% | −3,439.5% | −3,441.7% | −3,461.8% | −1,943.4% | −2,756.2% | −1,858.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RNA's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RNA financial results
In fiscal year 2025 (ended December 31, 2025), Atrium Therapeutics reported revenue of $18.6 million, up 70.9% from the year before. It had a net loss of $76.7 million, a net profit margin of −411.9%. Diluted earnings per share came to −$4.97. Over five years revenue grew at an average rate of 22.4% a year.
See the RNA stock overview for the latest quote and news, or the RNA chart for price history and technical indicators.
RNA income statement FAQ
What is Atrium Therapeutics's annual revenue?
Atrium Therapeutics reported total revenue of $18.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 70.9% from $10.9 million the previous year.
Is Atrium Therapeutics profitable?
No. Atrium Therapeutics reported a net loss of $76.7 million in fiscal 2025, a net profit margin of −411.9%; its operating margin was −412.6%.
What is Atrium Therapeutics's gross margin?
Atrium Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Atrium Therapeutics kept $100 after the direct cost of its products and services.
How much does Atrium Therapeutics spend on research and development?
Atrium Therapeutics spent $53.8 million on research and development in fiscal 2025, 288.7% of revenue.
How fast is Atrium Therapeutics growing?
Revenue grew 22.4% a year on average over the last five fiscal years, from $6.8 million to $18.6 million.
What are Atrium Therapeutics's earnings per share?
Atrium Therapeutics earned $-4.97 per diluted share in fiscal 2025, compared with $-2.89 a year earlier.
When will Atrium Therapeutics report its next earnings?
Atrium Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Atrium Therapeutics's fiscal year end?
Atrium Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.